tradingkey.logo
tradingkey.logo
Buscar

Grail Inc

GRAL
Añadir a la lista de seguimiento
61.260USD
-0.380-0.62%
Cierre 05/11, 16:00ETCotizaciones retrasadas 15 min
2.52BCap. mercado
PérdidaP/E TTM

Más Datos de Grail Inc Compañía

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.

Información de Grail Inc

Símbolo de cotizaciónGRAL
Nombre de la empresaGrail Inc
Fecha de salida a bolsaJun 12, 2024
Director ejecutivoRagusa (Robert)
Número de empleados1000
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección1525 O'brien Drive
CiudadMENLO PARK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94025
Teléfono18336942553
Sitio Webhttps://grail.com/
Símbolo de cotizaciónGRAL
Fecha de salida a bolsaJun 12, 2024
Director ejecutivoRagusa (Robert)

Ejecutivos de Grail Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.93K
+59.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
28.39K
+63.60%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
16.43K
-314.97%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--
Mr. Andy Partridge
Mr. Andy Partridge
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Steve Mizell
Mr. Steve Mizell
Independent Director
Independent Director
--
--
Mr. Alex Dobbin
Mr. Alex Dobbin
IR Contact Officer
IR Contact Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Aaron Freidin
Mr. Aaron Freidin
Chief Financial Officer
Chief Financial Officer
103.89K
+7.89%
Mr. Gregory L. (Greg) Summe
Mr. Gregory L. (Greg) Summe
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
30.93K
+59.09%
Mr. William J. (Bill) Chase
Mr. William J. (Bill) Chase
Independent Director
Independent Director
28.39K
+63.60%
Ms. Sarah Krevans
Ms. Sarah Krevans
Independent Director
Independent Director
16.43K
-314.97%
Mr. Robert (Bob) Ragusa
Mr. Robert (Bob) Ragusa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Joshua (Josh) Ofman, M.D.
Mr. Joshua (Josh) Ofman, M.D.
President
President
--
--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
Por negocioUSD
Nombre
Ganancia
Proporción
Screening
138.60M
94.18%
Development Services
8.57M
5.82%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
137.09M
93.15%
International
10.08M
6.85%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Screening
138.60M
94.18%
Development Services
8.57M
5.82%

Estadísticas de accionistas

Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.80%
Farallon Capital Management, L.L.C.
5.46%
Baker Bros. Advisors LP
4.86%
PRIMECAP Management Company
4.28%
State Street Investment Management (US)
4.26%
Otro
75.34%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
5.80%
Farallon Capital Management, L.L.C.
5.46%
Baker Bros. Advisors LP
4.86%
PRIMECAP Management Company
4.28%
State Street Investment Management (US)
4.26%
Otro
75.34%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
26.13%
Investment Advisor/Hedge Fund
21.44%
Hedge Fund
16.74%
Research Firm
7.21%
Corporation
3.03%
Individual Investor
1.69%
Venture Capital
1.07%
Private Equity
0.55%
Pension Fund
0.54%
Otro
21.59%

Participación institucional

Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
1071
33.74M
78.63%
+1.76M
2025Q4
993
25.86M
66.33%
-6.45M
2025Q3
934
24.89M
69.05%
-6.05M
2025Q2
874
30.08M
83.61%
-1.68M
2025Q1
859
29.51M
82.19%
-2.62M
2024Q4
810
31.24M
92.16%
+4.27M
2024Q3
748
27.13M
81.56%
+4.49M
2024Q2
646
27.14M
86.18%
+27.14M
2024Q1
2
135.00
0.00%
+135.00

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
2.49M
6.07%
+368.34K
+17.35%
Dec 31, 2025
Farallon Capital Management, L.L.C.
2.34M
5.71%
+734.02K
+45.63%
Dec 31, 2025
Baker Bros. Advisors LP
2.09M
5.08%
+455.21K
+27.92%
Dec 31, 2025
PRIMECAP Management Company
1.84M
4.48%
-182.26K
-9.02%
Dec 31, 2025
State Street Investment Management (US)
1.83M
4.46%
+510.55K
+38.77%
Dec 31, 2025
Illumina Inc
1.30M
3.17%
-2.20M
-62.82%
Dec 31, 2025
CRCM L.P.
1.07M
2.61%
-728.28K
-40.45%
Dec 31, 2025
Arbiter Partners Capital Management, LLC
1.04M
2.52%
-300.00
-0.03%
Dec 31, 2025
Deep Track Capital LP
1.02M
2.49%
+1.02M
--
Dec 31, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ROBO Global Healthcare Technology & Innovation ETF
3.75%
Clough Select Equity ETF
2.7%
Clough Hedged Equity ETF
2.53%
Franklin Genomic Advancements ETF
2.49%
First Trust Small Cap Growth AlphaDEX Fund
1.08%
State Street SPDR S&P Biotech ETF
0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
0.71%
Direxion Daily S&P Biotech Bull 3X Shares
0.59%
ProShares Ultra Nasdaq Biotechnology
0.48%
Invesco RAFI US 1500 Small-Mid ETF
0.42%
Ver más
ROBO Global Healthcare Technology & Innovation ETF
Proporción3.75%
Clough Select Equity ETF
Proporción2.7%
Clough Hedged Equity ETF
Proporción2.53%
Franklin Genomic Advancements ETF
Proporción2.49%
First Trust Small Cap Growth AlphaDEX Fund
Proporción1.08%
State Street SPDR S&P Biotech ETF
Proporción0.97%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.71%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.59%
ProShares Ultra Nasdaq Biotechnology
Proporción0.48%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0.42%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
KeyAI